LncRNA SNHG6 is Associated with Poor Prognosis of Gastric Cancer and Promotes Cell Proliferation and EMT through Epigenetically Silencing p27 and Sponging miR-101-3p

Kai Yan, Jie Tian, Wenzheng Shi, Hao Xia, Yuanfang Zhu

Department of Gastrointestinal Surgery, Clinical Medical College of Yangzhou University (Northern Jiangsu People’s Hospital), Yangzhou, Department of Pathology, Clinical Medical College of Yangzhou University (Northern Jiangsu People’s Hospital), Yangzhou, Department of General Surgery, The First Hospital of Tsinghua University, Beijing, China

Key Words
Gastric cancer • SNHG6 • EZH2 • p27 • miR-101-3p • ZEB1 • EMT

Abstract
Background/Amis: Long non-coding RNAs (lncRNAs), a novel class of transcripts, have been shown to play critical roles in diverse cellular biological processes, including tumorigenesis. Small nucleolar RNA host gene 6 (SNHG6) regulates various biological processes in cancer cells. However, the biological role of SNHG6 in gastric cancer still remains to be explored. The aim of this study is to investigate the characteristic of the SNHG6 in gastric cancer.

Methods: Quantitative real-time polymerase chain reaction (qRT-PCR) was used to measure the expression of SNHG6 in gastric cancer tissues and cell lines. MTT assays, colony formation assays were used to determine the impact of SNHG6 on tumorigenesis. Flow cytometric analysis of cell cycle and apoptosis was performed to measure the effect of SNHG6 on cell cycle and apoptosis rate. Transwell assay was performed to measure the effect of SNHG6 on cell migration. Western blotting and immunofluorescence were utilized to examine the effect of SNHG6 on epithelial–mesenchymal transition (EMT) of GC cells. Chromatin immunoprecipitation (ChIP), RNA immunoprecipitation (RIP), RNA-pulldown and luciferase reporter assays were employed to dissect molecular mechanisms.

Results: In this study, we revealed that SNHG6 was overexpressed in gastric cancer tissues and cell lines. High expression levels of SNHG6 were associated with invasion depth, lymph node metastasis, distant metastasis and tumor/node/metastasis (TNM) stage, and predicted poor prognosis. Loss-of-function assays revealed that silenced SNHG6 obviously inhibited gastric cancer cell growth, weakened cell migration capacity and suppressed the EMT processes of gastric cancer cells. Additionally, ChIP, RIP, RNA-pulldown and luciferase reporter assays evidenced that SNHG6 could epigenetically silenced p27 and could competitively sponging miR-101-3p thereby regulating zinc finger E-box-binding homeobox 1 (ZEB1).

Conclusion: In summary,
our findings demonstrated that SNHG6 acted as an oncogene in gastric cancer cells through regulating miR-101-3p/ZEB1 at a post-transcriptional level and silencing expression at a transcriptional level by recruiting enhancer of zeste homolog 2 (EZH2) to the promoter of p27. SNHG6 might serve as a candidate prognostic biomarker and a target for novel therapies of gastric cancer patients.

Introduction

Gastric cancer (GC) is one of the most common malignancies and the second leading cancer-related deaths worldwide [1, 2]. Despite many efforts have been made in diagnostic techniques and therapeutic measures, the clinical outcome of GC patients still remain unsatisfied [3, 4]. Since gastric carcinogenesis is a complicated biological process involving multiple oncogenes or tumor suppressors' dysregulation [5-10], investigating the molecular mechanisms is essential for exploring sensitive or effective biomarkers for early diagnosis and novel treatment for improving GC patients' survival rate.

Currently, with development of sequencing technologies and the deepening of researches, many long non coding RNAs (lncRNAs), a class of transcripts longer than 200nt with little or no protein-coding potential, are uncovered and investigated. Because of involving in multiple cellular biological processes especially in tumorigenesis [11-13], lncRNAs have been attracting many researchers attention. For instance, lncRNA Unigene56159 promotes epithelial-mesenchymal transition of hepatocellular carcinoma cells at a post-transcriptional level through sponging miR-140-5p [14]. Zhou et al. reported that the interaction between miR-141 and lncRNA-H19 in regulating cell proliferation and migration in gastric cancer [15]. In addition to post-transcriptional level, TUG1 was involved in the transcriptional repression of the CELF1 and regulated non-small cell lung cancer progression by binding to polycomb repressive complex 2 (PRC2) [16]. Recently, plenty lncRNAs have been reported to play critical role in tumorigenesis through recruiting PRC2. PRC2, a methyltransferase composed with enhancer of zeste homolog 2 (EZH2), suppressor of zeste 12 (SUZ12) and embryonic ectoderm development (EED), can modulate gene expression through catalyzing the di- and trimethylation of lysineresidue 27 of histone 3 (H3K27me3). The interaction between PRC and lncRNAs has been reported in multiple cancers [17-19].

Currently, some snoRNAs exhibit differential expression patterns in various human cancers and demonstrate the ability to affect cell transformation, tumorigenesis, and metastasis. snoRNA host gene 6 (SNHG6) have been demonstrated to be as a potential oncogene involved in the initial and development of hepatocellular carcinoma [20, 21]. However, activities of SNHG6 in GC tumorigenesis have not been well characterized, which prompted us to explore the role of SNHG6 in human GC. In our study, we revealed that SNHG6 was significantly increased in GC tissues, cell lines and was associated with poor prognosis of GC patients. Additionally, silenced SNHG6 inhibited GC cell proliferation, migration and reversed EMT to MET. Mechanism experiments uncovered that si-SNHG6 mediated growth inhibition was attributed to its influence on cell cycle through interacting with PRC2 and epigenetic silencing p27, while si-SNHG6 mediated migration-inhibition was through sponging miR-101-3p and thus regulating the expression of ZEB1. Our study may provide a strategy and facilitate the development of lncRNA-directed diagnostics and therapeutics against GC.

Materials and Methods

Clinical specimens

GC specimens and the corresponding adjacent tissues were collected from patients with GC at Department of Gastrointestinal Surgery, Clinical Medical College of Yangzhou University (Northern Jiangsu People's Hospital) between 2010 and 2013. All the informed consent was obtained. The diagnosis of GC
was histopathologically confirmed and no local or systemic treatment was conducted before surgery. The
protocols used in the study were approved by the Hospital’s Protection of Human Subjects Committee.

Cell culture and transfection

GC cell lines (MGC-803, AGS, SGC-7901, BGC-823), in comparison to normal gastric epithelial cell line
(GES-1) were purchased from the Cell Bank of Type Culture Collection (CBTCC, Chinese Academy of Sciences,
Shanghai, China). MGC-803 and BGC-823 cells were cultured in RPMI 1640 (Invitrogen); GES, SGC-7901 and
AGS cells were cultured in DMEM supplemented with 10% fetal bovine serum (Gibco, Carlsbad, CA, USA).
The cells were washed with 1*phosphate buffer saline (PBS) (pH7.4) and then transiently transfected with
50 nmol/l si-NC, si-SNHG6 or si-p27 using Lipofectamine 2000 (Invitrogen) following the manufacturer’s
instructions.

RNA extraction and qRT-PCR assays

Total RNA from specimens and cells was isolated with TRIzol reagent (Invitrogen, Karlsruhe, Germany)
based on the manufacturer’s instructions. Quantitative real-time polymerase chain reaction (qRT-PCR) was
performed using the PrimeScript RT Reagent Kit and SYBR Premix Ex Taq (TaKaRa, Dalian, China) following
the manufacturer’s instructions. The results were normalized to the expression of glyceraldehyde-3-
phosphate dehydrogenase (GAPDH). The specific primers used are presented in Table 1. PCR results were
analyzed to obtain Ct values of amplified products, and data was analyzed by adopting 2^-ΔΔCt method.

Cell viability

Cell viability was assessed via 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyl-trtrazolium bromide (MTT)
assay. 5 × 10^3 cells/well transfected with indicated vector were seeded in a 96-well flat-bottomed plate for
24 h and cultured in normal medium. At 0, 24, 48, 72 h and 96h after transfection, the MTT solution (5 mg/ ml, 20 μl) was added to each well. Following incubation for 4 h, the media was removed and 100 μl DMSO
were added to each well. The relative number of surviving cells was assessed by measuring the optical
density (O.D.) of cell lysates at 560 nm. All assays were performed in triplicate.

Colony formation assay

Cells (500 cells/ well) transfected with indicated vector were plated in 6-well plates and incubated at 37 °C. Two weeks later, the cells were fixed and stained with 0.1% crystal violet. The number of visible
colonies was counted manually.

Cell migration assay

Cell migration were measured by transwell chamber (8 um pore size, Corning). 48 h after transfection,
cells in serum-free media were placed into the upper chamber. Media containing 10% PBS was added into the
lower chamber. Following 48 h incubation, cells remaining in upper membrane were wiped off, while cells that migrated were fixed in methanol, stained with 0.1% crystal violet and counted under a microscope.
Three independent experiments were carried out. Cells adhering to the bottom surface of the membrane
were counted in five randomly selected areas under microscope field. Each experiment was repeated three
times.
Flow cytometric analysis of apoptosis

Cells transfected with indicated plasmid or negative control were reaped after 48 hours. Apoptosis were performed using flow cytometric analyses with Annexin V: FITC Apoptosis Detection Kits (BD Biosciences, USA), according to the manufacturer's instructions. All samples were assayed in triplicate.

Flow cytometric analysis of cell cycle distribution

Cells were collected directly or 48 hours after transfection and washed with ice-cold phosphate-buffered saline (PBS), and fixed with 70% ethanol overnight at -20°C. Fixed cells were rehydrated in PBS for 10 minutes and incubated in RNase A (1mg/ml) for 30 min at 37°C, then the cells were subjected to PI/RNase staining followed by flow cytometric analysis using a FACScan instrument (Becton Dickinson, Mountain View, CA). All samples were assayed in triplicate.

Immunofluorescence

Cells seeded on glass coverslips in 6-well plates were fixed in 4% formaldehyde solution and permeabilized with 0.5% Triton X-100/PBS. Cells were blocked with 5% BSA-PBS for 1h at room temperature and incubated with primary antibody at 4°C overnight, followed by incubation with fluorescent-dye conjugated secondary antibody (Invitrogen) for 1h, and then stained with DAPI. Finally, images were taken under an inverted fluorescence microscope.

Luciferase assay

Luciferase activity was measured using a Dual Luciferase Assay Kit (Promega, Madison, WI, USA) according to the manufacturer's instructions.

Western blot analysis

Total protein was extracted from cells and tumor tissues using RIPA lysis buffer. Extracted proteins were mixed with loading buffer, subject to 10% SDS-PAGE and transferred to PVDF membranes, which were subsequently blocked in a 5% solution of non-fat milk for 2 h. The membranes were subsequently incubated with antibodies specific to E-cadherin, N-cadherin, Vimentin, β-catenin and ZEB1 (Abcam, Cambridge, UK) for 16 h. GAPDH expression was used as an internal reference.

Subcellular fractionation location

The separation of nuclear and cytosolic fractions was performed using the PARIS Kit (Life Technologies) according to the manufacturer's instructions. In detail, Collect up to 10^7 fresh cultured GC cells, wash once in PBS, and place washed cells on ice; resuspend cells in 100–500 μL ice-cold cell fractionation buffer; incubate on ice 5–10 min; centrifuge samples 1–5 min at 4°C and 500 ×g; carefully aspirate the cytoplasmic fraction away from the nuclear pellet and wash the nuclear pellet in ice-cold cell fractionation buffer; then lyse nuclear pellet in cell disruption buffer and split the sample for RNA isolation. For RNA isolation, mix the lysate with an equal volume of 2X Lysis/Binding Solution; add 1 "sample volume" of 100% ethanol to the mixture; wash with wash solution; elute RNA with elute solution. RNAs extracted from each of the fractions were subjected to following RT-qPCR analysis to demonstrate the levels of nuclear control transcript (U6), cytoplasmic control transcript (GAPDH), SNHG6. PCR primers were provided in Table 3.

Chromatin immunoprecipitation (ChIP)

We performed chromatin immunoprecipitation (ChIP) using the EZ ChIP™ Chromatin Immunoprecipitation Kit for cell line samples (Millipore, Bedford, MA). Briefly, we sonicated the crosslinked chromatin DNA into 200-to 500-bp fragments. Normal mouse IgG was used as the negative control. The primer sequences are listed in Table 3. The antibodies for the ChIP assays were obtained from Millipore. Quantification of the immunoprecipitated DNA was performed using qPCR with SYBR Green Mix (Takara). The ChIP data were calculated as a percentage relative to the input DNA using the equation 2^[Input Ct-Target Ct] × 0.1 × 100.

RNA immunoprecipitation (RIP)

We performed RNA immunoprecipitation (RIP) experiments using the Magna RIP™ RNA-Binding Protein Immunoprecipitation Kit (Millipore, USA) according to the manufacturer's instructions. The
antibodies for the RIP assays of Ago2, EZH2, EED, SUZ12 were obtained from Abcam. The total RNAs were
the input controls.

RNA pulldown assay

Biotin-labeled RNAs were transcribed in vitro with the Biotin RNA Labeling Mix (Roche Diagnostics) and T7 RNA polymerase (Roche Diagnostics), treated with RNase-free DNase I (Roche), and purified with an RNeasy Mini Kit (Qiagen, Valencia, CA). Next, 1 mg whole-cell lysates from BGC-823 cells was incubated with 3 μg of purified biotinylated transcripts for 1 h at 25 °C. Complexes were isolated with streptavidin agarose beads (Invitrogen). The beads were washed briefly three times and boiled in sodium dodecyl sulfate (SDS) buffer, and the retrieved protein was detected using the standard western blot technique.

Statistical analysis

The SPSS 17.0 statistical analysis software was used for the statistical analysis of the experimental data. The significance of differences between groups was estimated by Student’s t-test. Multiple group comparisons were analyzed with one-way ANOVA. Statistically significant correlation between SNHG6 and ZEB1 or p27 expression levels in GC tissues was analyzed by Spearman’s correlation analysis. The overall survival probability was analyzed using Kaplan-Meier methods and evaluated using the log-rank test. Cox proportional hazards regression model was generated to identify factors associated with overall survival through a multivariate survival analysis of GC. A P value less than 0.05 were considered significant.

Results

SNHG6 is upregulated in human GC tissues and cell lines

To explore the function of SNHG6 in GC, we first performed qRT-PCR to measure the level of SNHG6 in 78 GC tissues and cell lines. Comparing with matched adjacent normal tissues, SNHG6 level was significantly increased in GC tissues (Fig. 1A, p<0.01). High level of SNHG6 was also confirmed in four GC cell lines (MGC-803, AGS, SGC-7901, BGC-823), in comparison to normal gastric epithelial cell line (GES-1) (Fig. 1B, p<0.01). Furthermore, we evaluated the correlation of SNHG6 and clinical pathological features. The median value of SNHG6 in all GC tissues was used as a cutoff value, and all samples were divided into two group (high expression group n=45 vs. low expression group n =33). As shown in Table 2, increased level of SNHG6 was significantly correlated with tumor invasion depth (p=0.001), lymph node metastasis (p=0.012), distant metastasis (p=0.006) and TNM stage (p=0.001), but was no significant correlation with sex, age and histological grade (p>0.05). Additionally,
Yan et al.: SNHG6 Promotes Cell Proliferation and EMT in Gastric Cancer

Kaplan–Meier method analysis (log-rank test) determined that patients with high level of SNHG6 had a significantly shorter overall survival than those with low level of SNHG6 (Fig. 1C, P = 0.000). Proportional hazards method analysis revealed that high level of SNHG6 could be acted as prognostic factor (Table 3, P = 0.009). These data together indicated that SNHG6 might be involved in the progression of GC.

Silenced SNHG6 suppresses cell proliferation through causing G1 arrest and inducing apoptosis in GC cells

To determine the biological function of SNHG6 in GC cells, we selected SGC-7901 and BGC-823 cells which express relative high level of SNHG6 and transfected two cell lines with SNHG6 specific siRNA (Fig. 2A). To assess the effect of SNHG6 on GC cell proliferation ability, we performed MTT and colony formation. As shown in Fig. 2B, results from MTT assays present that cells silenced SNHG6 displayed a weakened viability. Similarly, colony formation assays revealed that colony-formation efficiency was significantly suppressed when SNHG6 was knockdown (Fig. 2C). To determine SNHG6 pro-proliferation mechanism, flow cytometric analysis of cell cycle distribution and apoptosis rate were utilized. As obtained in Fig. 2D-E, silenced SNHG6 caused G0/G1 arrest and significantly increased the apoptosis rate. These investigations proved the oncogene effect of SNHG6 on GC cells and such function was attributed to its influence on cell cycle and apoptosis.

SNHG6 knockdown represses cell migration and reverses EMT to MET

To examine the effect of SNHG6 on cell migration capacity, transwell assays were performed and the results revealed that deletion of SNHG6 decreased BGC-823 and SGC-7901 cell migration capacity (Fig. 3A). As EMT is a critical process contributing to tumor metastasis, we assessed the function of SNHG6 on EMT markers. As observed in Fig. 3B, western blot showed that inhibition of SNHG6 decreased the mesenchymal markers (N-cadherin, vimentin) whereas increased epithelial markers (E-cadherin, β-catenin); and the level of ZEB1, a crucial transcription factor that regulates EMT was

Table 2. Correlation between SNHG6 Expression and Clinical Features. (n=78)

<table>
<thead>
<tr>
<th>Variable</th>
<th>LncRNA-SNHG6 Expression</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>15</td>
<td>17</td>
</tr>
<tr>
<td>Female</td>
<td>18</td>
<td>28</td>
</tr>
<tr>
<td>Age</td>
<td>60</td>
<td>19</td>
</tr>
<tr>
<td>&gt;60</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Histological grade</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low or undifferent</td>
<td>20</td>
<td>24</td>
</tr>
<tr>
<td>Middle or high</td>
<td>13</td>
<td>21</td>
</tr>
<tr>
<td>Tumor invasion depth</td>
<td>T1</td>
<td>22</td>
</tr>
<tr>
<td>≥T2</td>
<td>11</td>
<td>32</td>
</tr>
<tr>
<td>Lymph node metastasis</td>
<td>N0</td>
<td>14</td>
</tr>
<tr>
<td>≥N1</td>
<td>19</td>
<td>21</td>
</tr>
<tr>
<td>Distant metastasis</td>
<td>M0</td>
<td>21</td>
</tr>
<tr>
<td>M1</td>
<td>12</td>
<td>32</td>
</tr>
<tr>
<td>TNM stage</td>
<td>I-II</td>
<td>20</td>
</tr>
<tr>
<td>III-IV</td>
<td>13</td>
<td>33</td>
</tr>
</tbody>
</table>

Table 3. Multivariate analysis of prognostic parameters in patients with gastric cancer by Cox regression analysis. Proportional hazards method analysis showed a positive, independent prognostic importance of SHNG6 expression (P = 0.009), in addition to the independent prognostic impact of Lymph node metastasis (P = 0.000) and TNM stage (P=0.011). 'P < 0.05 was considered statistically significant

<table>
<thead>
<tr>
<th>Variable</th>
<th>Category</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender</td>
<td>Male</td>
<td>0.898</td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td></td>
</tr>
<tr>
<td>Age</td>
<td>≤60</td>
<td>0.130</td>
</tr>
<tr>
<td></td>
<td>&gt;60</td>
<td></td>
</tr>
<tr>
<td>Histological grade</td>
<td>Low or undifferent</td>
<td>0.265</td>
</tr>
<tr>
<td></td>
<td>Middle or high</td>
<td></td>
</tr>
<tr>
<td>Tumor invasion depth</td>
<td>T1</td>
<td>0.309</td>
</tr>
<tr>
<td></td>
<td>≥T2</td>
<td></td>
</tr>
<tr>
<td>Lymph node metastasis</td>
<td>N0</td>
<td>0.000*</td>
</tr>
<tr>
<td></td>
<td>≥N1</td>
<td></td>
</tr>
<tr>
<td>Distant metastasis</td>
<td>M0</td>
<td>0.069</td>
</tr>
<tr>
<td></td>
<td>M1</td>
<td></td>
</tr>
<tr>
<td>TNM stage</td>
<td>I-II</td>
<td>0.011*</td>
</tr>
<tr>
<td></td>
<td>III-IV</td>
<td></td>
</tr>
<tr>
<td>SNHG6 expression</td>
<td>Low</td>
<td>0.009*</td>
</tr>
<tr>
<td></td>
<td>High</td>
<td></td>
</tr>
</tbody>
</table>
also reduced significantly. Consistent with western blot, results from immunofluorescence further verified the effect of SNHG6 on EMT formation (Fig. 3C). These findings revealed that SNHG6 potentially influenced the migration capacity and EMT phenotype formation of GC cells and such function might be exerted by regulating ZEB1 expression.

\[
\text{SNHG6 exerted its function through epigenetically silencing p27 transcription and sponging miR-101-3p.}
\]

To investigate the underlying mechanism of SNHG6 in GC cells, we measured the percentage of SNHG6 in the cytoplasmic and nuclear fractions of BGC-823 and SGC-7901 cells. As observed in Fig. 4A, SNHG6 located both in cytoplasm and nucleus. Since accumulating documents have revealed that lncRNAs could interacted with PRC2 and SNHG6 has been identified as competing endogenous (ce)RNAs regulating ZEB1 through sponging miRNA-101-3p [21], we speculated that the potential mechanism of SNHG6 in GC cells might involve both transcriptional and post-transcriptional regulation. To test this prediction, we first confirmed the regulatory pathway between SNHG6 and miR-101-3p. As revealed in Fig. 4B-D, results from RIP, luciferase reporter assay and biotin-avidin pulldown assay indicated that SNHG6 regulated miR-101-3p in a ceRNA manner. ZEB1, a key regulator of EMT, is identified as a target of miR-101-3p by luciferase reporter assay and western blot assay (Fig. 4E-F).
Therefore, the pro-metastasis function of SNHG6 was through regulating ZEB1 via acting as a ceRNA competitively sponging miR-101-3p.

Next, we investigated the pro-proliferation mechanism of SNHG6. Due to the effect of SNHG6 on cell cycle, we measured the level CKIs (p15, p16, p17, p21, p27, p57). As shown in Fig. 5A, the p27 was significantly increased when SNHG6 was deleted. Since SNHG6 also located in nucleus, we speculated that SNHG6 was involved in transcriptional regulation. To confirm the hypothesis, we assessed the relationship between SNHG6 and PRC2. RIP results showed that SNHG6 could directly bind with EZH2 in BGC-823 and SGC-7901 cells but not bind with SUZ12 and EED (Fig. 5B), while U1 binding with SNRNP70 was used as positive control (Fig. 5C). Moreover, RNA-pulldown assay also confirmed that SNHG6 indeed binds with EZH2 in BGC-823 cells (Fig. 5D). And silenced EZH2 increased p27 expression both in mRNA and protein level (Fig. 5E). To determine whether SNHG6 is involved in transcriptional regulation through recruiting EZH2 to the target gene promoter, we applied ChIP assay. As revealed in Fig. 5F, the binding level of EZH2 and H3K27me3 in the promoter of p27 was significantly reduced when SNHG6 was knockdown. These results indicate that SNHG6 epigenetically modulate the expression of p27 through interacting with EZH2.

ZEB1 and p27 are involved in the oncogenic function of SNHG6 in GC cells

To verify the function of ZEB1 and p27 in GC, we measured the level of ZEB1 and p27 in GC tissues and corresponding normal tissues. As shown in Fig. 6A, the level of ZEB1 was obviously increased in GC tissues and was positively correlated with the level of SNHG6; whereas the level of p27 was significantly decreased in GC tissues and was negatively
correlated with the level of SNHG6. Additionally, co-transfected ZEB1 and si-SNHG6 could abolish the anti-migration effect of si-SNHG6 of BGC-823 cells (Fig. 6B), and could reverse
the MET to EMT (Fig. 6C-D). And silenced p27 could abrogate the anti-growth effect, G0/G1 arrest and apoptosis mediated by si-SNHG6 in BGC-823 cells (Fig. 6E-F). These findings revealed that ZEB1 and P27 are involved in the oncogenic function of SNHG6 in GC.

Discussion

In the past decades, the biological function of microRNAs (miRNAs) have been deeply studied in plenty types of cancer, including GC [22-27]. Currently, the newly uncovered lncRNAs, emerged as important factors in cellular processes and human diseases, have been attracting more and more attentions of researchers. For example, novel lncRNA TUSC7 was identified dysregulated in colorectal cancer and regulating cell proliferation through sponging miR-211 [28]. And lncRNA TRPM2-AS was demonstrated as novel prognostic marker and therapeutic target in prostate cancer [29]. In present study, we revealed that the expression level of SNHG6 in GC tissues was significantly increased compared with corresponding
normal tissues. The high expression level of SNHG6 in GC patients was associated with invasion depth and TNM stage and positively correlated with poor prognosis and could be regarded as an independent prognostic indicator. Our findings indicated that SNHG6 acted as an oncogene and played a critical role in GC progression. It has been previously revealed that SNHG6 was upregulated in hepatocellular carcinoma (HCC) and regulated HCC progression. Despite the function of SNHG6 has been reported, the possible biological role and the underlying molecular mechanism of SNHG6 in GC has not been elucidated and still remains to be clarified. In our current study, the biological function of SNHG6 was explored by employing loss-of-function assay. We revealed that silenced SNHG6 could promote GC cell proliferation, migration and reverse EMT to MET. Mechanism experiments demonstrated that the growth-inhibition effect of si-SNHG6 was attributed to its influence on cell cycle and apoptosis, and si-SNHG6 mediated metastasis-inhibition and EMT to MET was dependent on its regulation on ZEB1.

In 2016, Chang et al. [21] demonstrated that SNHG6 plays an important role in the migration and EMT in HCCs through sponging miR-101-3p. In our study, mechanism experiments were performed and proved that si-SNHG6 mediated migration inhibition and EMT to MET was also through sponging miR-101-3p and thereby regulating the level of ZEB1. It has been studied that IncRNAs could interact with PRC2 and thereby epigenetically regulating the downstream targets [16, 17, 19, 30-33]. It is well known that activation of cyclin-D-CDK4/6 kinases or inactivation of the CKIs could cause cell cycle disorders and influence cell proliferation [34]. CKIs, as tumor suppressors, are responsible for the modulation of the activity of Cdk/cyclin complexes [35]. And the aberrant methylation such as PRC2-mediated histone methylation in the CKI gene promoter region is associated with
gene expression suppression [36-39]. Additionally, plenty of lncRNAs have been reported to modulate specific genetic loci through recruiting PRC2 and PRC2-mediated epigenetic regulation play important role in tumorigenesis [17, 30, 31, 40-42]. In present study, our finding demonstrated that the deletion of SNHG6 could epigenetically silence the expression of p27 through interacting with EZH2.

Collectively, our study demonstrated a SNHG6-mediated regulation of the GC cell proliferation, cell cycle, cell apoptosis through epigenetically silencing p27 and metastasis through sponging miR-101-3p. Importantly, we first reported that SNHG6 serving as a member of PRC2-mediated epigenetic regulation participated in the development of GC. Our study might provide a strategy and contribute to the development of lncRNA-directed diagnostics and therapeutics against GC.

Acknowledgement

The authors thank the laboratory members.

Disclosure Statement

No conflicts of interest to disclose.

Reference


